|
ES2165768B1
(es)
|
1999-07-14 |
2003-04-01 |
Almirall Prodesfarma Sa |
Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
|
|
AU6610001A
(en)
|
2000-06-27 |
2002-01-08 |
S A L V A T Lab Sa |
Carbamates derived from arylalkylamines
|
|
HUP0303529A3
(en)
|
2000-12-22 |
2008-03-28 |
Almirall Ag |
New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use
|
|
CN1250545C
(zh)
|
2000-12-28 |
2006-04-12 |
阿尔米雷尔普罗迪斯制药有限公司 |
新的奎宁环衍生物类及含有这类衍生物的药物组合物
|
|
AU2002360598B2
(en)
|
2001-12-14 |
2008-02-14 |
Medical College Of Georgia Research Institute, Inc. |
Methods and compositions for treatment of central nervous system disorders
|
|
JP4505227B2
(ja)
|
2001-12-20 |
2010-07-21 |
キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ |
１−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
|
|
ES2203327B1
(es)
|
2002-06-21 |
2005-06-16 |
Almirall Prodesfarma, S.A. |
Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
|
|
ES2204295B1
(es)
|
2002-07-02 |
2005-08-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de quinuclidina-amida.
|
|
NZ537584A
(en)
|
2002-07-08 |
2006-07-28 |
Ranbaxy Lab Ltd |
3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
|
|
TW200800953A
(en)
|
2002-10-30 |
2008-01-01 |
Theravance Inc |
Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
|
|
PE20040950A1
(es)
|
2003-02-14 |
2005-01-01 |
Theravance Inc |
DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
|
|
WO2004089898A1
(en)
|
2003-04-09 |
2004-10-21 |
Ranbaxy Laboratories Limited |
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
BRPI0409302A
(pt)
|
2003-04-11 |
2006-04-11 |
Ranbaxy Lab Ltd |
derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
|
|
AR044519A1
(es)
|
2003-05-02 |
2005-09-14 |
Novartis Ag |
Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
|
|
ATE435862T1
(de)
|
2003-05-28 |
2009-07-15 |
Theravance Inc |
Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
|
|
JP2007524641A
(ja)
|
2003-07-11 |
2007-08-30 |
セラヴァンス， インコーポレーテッド |
置換４−アミノ−１−ベンジルピペリジン化合物
|
|
ES2329586T3
(es)
|
2003-11-21 |
2009-11-27 |
Theravance, Inc. |
Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
WO2005087733A1
(en)
|
2004-03-11 |
2005-09-22 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
US7262205B2
(en)
|
2004-03-11 |
2007-08-28 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
EP1723109A1
(en)
|
2004-03-11 |
2006-11-22 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
WO2005087737A1
(en)
|
2004-03-11 |
2005-09-22 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
TW200538095A
(en)
|
2004-03-11 |
2005-12-01 |
Theravance Inc |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
JP2007528413A
(ja)
|
2004-03-11 |
2007-10-11 |
セラヴァンス， インコーポレーテッド |
ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
|
|
EP1723110A1
(en)
|
2004-03-11 |
2006-11-22 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
TWI341836B
(en)
|
2004-03-11 |
2011-05-11 |
Theravance Inc |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
ES2246170B1
(es)
*
|
2004-07-29 |
2007-04-01 |
Almirall Prodesfarma, S.A. |
Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
|
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
EP1866284A1
(en)
|
2005-03-10 |
2007-12-19 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
JP2008537931A
(ja)
|
2005-03-10 |
2008-10-02 |
セラヴァンス， インコーポレーテッド |
ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物
|
|
US7659403B2
(en)
|
2005-03-10 |
2010-02-09 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
US7629336B2
(en)
|
2005-03-10 |
2009-12-08 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
TW200714587A
(en)
|
2005-03-10 |
2007-04-16 |
Theravance Inc |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US7728144B2
(en)
|
2005-06-13 |
2010-06-01 |
Theravance, Inc |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
CA2618700A1
(en)
|
2005-08-22 |
2007-03-01 |
Targacept, Inc. |
Heteroaryl-substituted diazatricycloalkanes, methods for its preparation and use thereof
|
|
US7910708B2
(en)
|
2005-10-21 |
2011-03-22 |
Novartis Ag |
Anti-IL13 human antibodies
|
|
WO2007110782A1
(en)
*
|
2005-12-30 |
2007-10-04 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
GB0602778D0
(en)
|
2006-02-10 |
2006-03-22 |
Glaxo Group Ltd |
Novel compound
|
|
ATE549337T1
(de)
|
2006-04-21 |
2012-03-15 |
Novartis Ag |
Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
|
|
ES2298049B1
(es)
|
2006-07-21 |
2009-10-20 |
Laboratorios Almirall S.A. |
Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
|
|
EP1882691A1
(en)
*
|
2006-07-26 |
2008-01-30 |
CHIESI FARMACEUTICI S.p.A. |
Quinuclidine derivatives as M3 antagonists
|
|
KR20090073121A
(ko)
|
2006-09-29 |
2009-07-02 |
노파르티스 아게 |
Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
|
|
TW200825084A
(en)
*
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
|
RS51644B
(sr)
|
2007-01-10 |
2011-10-31 |
Irm Llc. |
Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
|
|
BRPI0806972A2
(pt)
*
|
2007-02-09 |
2014-04-08 |
Astellas Pharma Inc |
Composto cíclico contendo ponte azo
|
|
US20090010923A1
(en)
*
|
2007-04-24 |
2009-01-08 |
University Of Maryland, Baltimore |
Treatment of cancer with anti-muscarinic receptor agents
|
|
KR20100005730A
(ko)
|
2007-05-07 |
2010-01-15 |
노파르티스 아게 |
유기 화합물
|
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
|
KR101565469B1
(ko)
|
2007-10-01 |
2015-11-03 |
코멘티스, 인코포레이티드 |
알츠하이머병의 치료를 위한 알파 7 니코틴 아세틸콜린 수용체 리간드로서 퀴누클리딘-4-일메틸 1ｈ-인돌-3-카르복실레이트 유도체
|
|
EP2065385A1
(en)
*
|
2007-11-28 |
2009-06-03 |
Laboratorios SALVAT, S.A. |
Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
|
|
EA017919B1
(ru)
|
2007-12-10 |
2013-04-30 |
Новартис Аг |
Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
|
|
EP2231642B1
(en)
|
2008-01-11 |
2013-10-23 |
Novartis AG |
Pyrimidines as kinase inhibitors
|
|
EP2080507A1
(en)
*
|
2008-01-15 |
2009-07-22 |
CHIESI FARMACEUTICI S.p.A. |
Pharmaceutical formulations comprising an anticholinergic drug
|
|
EP2254598B1
(en)
|
2008-02-13 |
2013-07-10 |
Targacept, Inc. |
Combination of alpha 7 nicotinic agonists and antipsychotics
|
|
US20100055045A1
(en)
|
2008-02-26 |
2010-03-04 |
William Gerhart |
Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
|
|
NZ587561A
(en)
*
|
2008-02-26 |
2012-10-26 |
Elevation Pharmaceuticals Inc |
Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
|
|
EP2100598A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
EP2100599A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
US8268834B2
(en)
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
|
KR20110040818A
(ko)
|
2008-06-10 |
2011-04-20 |
노파르티스 아게 |
상피 나트륨 채널 차단제로서의 피라진 유도체
|
|
EP2154136A1
(en)
|
2008-08-08 |
2010-02-17 |
CHIESI FARMACEUTICI S.p.A. |
Quinuclidine carbonate derivatives and medicinal compositions thereof
|
|
US20100112606A1
(en)
*
|
2008-10-17 |
2010-05-06 |
Michael Armstrong |
Measurement and analysis of leukotrienes
|
|
EP2206712A1
(en)
|
2008-12-23 |
2010-07-14 |
CHIESI FARMACEUTICI S.p.A. |
"Alkaloid aminoester derivatives and medicinal composition thereof"
|
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
|
PL2391366T3
(pl)
|
2009-01-29 |
2013-04-30 |
Novartis Ag |
Podstawione benzimidazole do leczenia gwiaździaków
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
|
MY162604A
(en)
|
2009-08-17 |
2017-06-30 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
|
MX2012002179A
(es)
|
2009-08-20 |
2012-03-16 |
Novartis Ag |
Compuestos heterociclicos de oxima.
|
|
EP2813227A1
(en)
|
2009-10-22 |
2014-12-17 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
CN102947300B
(zh)
|
2010-06-22 |
2016-09-21 |
奇斯药制品公司 |
生物碱氨基酯衍生物及其药物组合物
|
|
UA107499C2
(uk)
|
2010-06-22 |
2015-01-12 |
Chiesi Farm Spa |
Склад сухого порошку, який містить антимускариновий засіб
|
|
ES2545812T3
(es)
|
2010-06-22 |
2015-09-16 |
Chiesi Farmaceutici S.P.A. |
Derivados aminoéster de alcaloides y composición medicinal de estos
|
|
CN102947299B
(zh)
|
2010-06-22 |
2015-07-15 |
奇斯药制品公司 |
生物碱氨基酯衍生物及其药物组合物
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
US8637516B2
(en)
|
2010-09-09 |
2014-01-28 |
Irm Llc |
Compounds and compositions as TRK inhibitors
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
WO2012069275A1
(en)
|
2010-11-26 |
2012-05-31 |
Chiesi Farmaceutici S.P.A. |
Glycine derivatives and their use as muscarinic receptor antagonists
|
|
KR101928505B1
(ko)
*
|
2011-01-28 |
2018-12-12 |
에스케이바이오팜 주식회사 |
피리돈 유도체 및 이를 포함하는 약학적 조성물
|
|
JP2014505088A
(ja)
|
2011-02-10 |
2014-02-27 |
ノバルティス アーゲー |
Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
|
|
US20120220557A1
(en)
|
2011-02-17 |
2012-08-30 |
Chiesi Farmaceutici S.P.A. |
Liquid propellant-free formulation comprising an antimuscarinic drug
|
|
EP2678016B1
(en)
|
2011-02-23 |
2016-08-10 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
|
AU2012220572A1
(en)
|
2011-02-25 |
2013-08-29 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
CN103917094B
(zh)
*
|
2011-03-18 |
2016-11-09 |
建新公司 |
葡萄糖基神经酰胺合酶抑制剂
|
|
EP2510928A1
(en)
|
2011-04-15 |
2012-10-17 |
Almirall, S.A. |
Aclidinium for use in improving the quality of sleep in respiratory patients
|
|
BR112013025682A2
(pt)
*
|
2011-04-29 |
2017-01-03 |
Chiesi Farm Spa |
Compostos, composição farmacêutica, uso de um composto, combinação e dispositivo
|
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
|
UY34329A
(es)
|
2011-09-15 |
2013-04-30 |
Novartis Ag |
Compuestos de triazolopiridina
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
ES2882807T3
(es)
|
2011-09-16 |
2021-12-02 |
Novartis Ag |
Heterociclil carboxamidas N-sustituidas
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
WO2013038386A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Heterocyclic compounds for the treatment of cystic fibrosis
|
|
US20130209543A1
(en)
|
2011-11-23 |
2013-08-15 |
Intellikine Llc |
Enhanced treatment regimens using mtor inhibitors
|
|
WO2013098145A1
(en)
|
2011-12-30 |
2013-07-04 |
Chiesi Farmaceutici S.P.A. |
Quinuclidine esters of 1-azaheterocyclylacetic acid as antimuscarinic agents, process for their preparation and medicinal compositions thereof
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
CN110507654A
(zh)
|
2012-04-03 |
2019-11-29 |
诺华有限公司 |
有酪氨酸激酶抑制剂的组合产品和其应用
|
|
MA37975B2
(fr)
|
2012-09-11 |
2021-03-31 |
Genzyme Corp |
Inhibiteurs de synthase de glucosylcéramide
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
COMBINING KINASE INHIBITORS AND USES THEREOF
|
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
|
EP3134397A1
(en)
|
2014-04-24 |
2017-03-01 |
Novartis AG |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
PL3134395T3
(pl)
|
2014-04-24 |
2018-07-31 |
Novartis Ag |
Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
|
|
US10112926B2
(en)
|
2014-04-24 |
2018-10-30 |
Novartis Ag |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
US20170166561A1
(en)
|
2014-07-11 |
2017-06-15 |
Alpharmagen, Llc |
Quinuclidine compounds for modulating alpha7-nicotinic acetylcholine receptor activity
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
KR20170036037A
(ko)
|
2014-07-31 |
2017-03-31 |
노파르티스 아게 |
조합 요법
|
|
US9724340B2
(en)
|
2015-07-31 |
2017-08-08 |
Attenua, Inc. |
Antitussive compositions and methods
|
|
US12527776B2
(en)
|
2019-02-04 |
2026-01-20 |
Genzyme Corporation |
Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS)
|
|
EP3980121A1
(en)
|
2019-06-10 |
2022-04-13 |
Novartis AG |
Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
|
|
PH12022550468A1
(en)
|
2019-08-28 |
2023-03-06 |
Novartis Ag |
Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
|
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
|
|
EP4100009A1
(en)
|
2020-02-03 |
2022-12-14 |
Genzyme Corporation |
Methods for treating neurological symptoms associated with lysosomal storage diseases
|
|
KR20230043024A
(ko)
|
2020-07-24 |
2023-03-30 |
젠자임 코포레이션 |
벤글루스타트를 포함하는 제약 조성물
|